Management of children with idiopathic short stature

European Journal of Endocrinology (2006) 155 S35–S38

ISSN 0804-4643

Management of children with idiopathic short stature Leo Dunkel Kuopio University and University Hospital, PO Box 1777, 70211 Kuopio, Finland (Correspondence should be addressed to L Dunkel; Email: [email protected])

Abstract The Food and Drug Administration (FDA) approved the use of biosynthetic GH for the treatment of children with idiopathic short stature (ISS) in the US in 2003. Primarily, the decision was based on two studies: a randomized placebo-controlled study and a dose–response study, both demonstrating an increase in adult height over the predicted height at baseline and over placebo-treated controls by an average of 4–7 cm. Despite these data and FDA approval of GH treatment for ISS, there is still a significant controversy among paediatric endocrinologists about how, and to what extent, GH should be used in this indication. GH is clearly efficacious in several growth disorders and has the potential to alleviate debilitating short stature. However, it has been questioned whether ISS should be considered a condition warranting pharmacological treatment, whether the degree of morbidity of untreated ISS is clinically significant, and whether improved psychosocial status or well-being is achieved through GH treatment and height gain. The benefits must outweigh treatment costs and risks to justify GH treatment in ISS. The safety of GH treatment in ISS has been the main subject in two recent articles from pharmaceutical companies that conducted the pioneering studies mentioned earlier. No new safety concerns were observed in the ISS populations, but there were some limitations in study designs that prevent clinicians, their patients and families from ‘resting assured’. Studies addressing these controversial issues are needed before the widespread use of GH treatment in ISS is warranted. European Journal of Endocrinology 155 S35–S38

Introduction The specific aetiology for short stature in children is sometimes difficult to identify. If a healthy but small child has normal growth hormone (GH) responses to provocation tests, the condition may be termed idiopathic short stature (ISS) or non-GH-deficient short stature (1, 2). In a survey by the Lawson Wilkins Pediatric Endocrine Society, 94% of paediatric endocrinologists recommended GH therapy for some children with ISS, despite normal GH secretion (3). By now, thousands of children with ISS have received GH therapy (4, 5).

Efficacy of GH treatment in ISS Several randomized trials have demonstrated that GH administration accelerates growth in the short term (6–8). Furthermore, most, but not all, nonrandomized long-term studies suggest that GH increases This paper was presented at the 4th Ferring Pharmaceuticals International Paediatric Endocrinology Symposium, Paris (2006). Ferring Pharmaceuticals has supported the publication of these proceedings.

q 2006 Society of the European Journal of Endocrinology

adult height of children with idiopathic short stature (9–18). Thus, in the past, many children with idiopathic short stature received GH treatment despite a lack of definitive evidence for its efficacy. A meta-analysis (19), which included one small randomized trial (20) and three studies with non-randomized, untreated controls, reported a 5–6 cm difference in adult height between treatment (mean GH dose, 0.31 mg/kg per week) and control groups. Two recent studies, a randomized placebo-controlled study (21) and a dose–response study (22) have provided firm, if not conclusive, evidence for the efficacy of GH treatment in ISS. In the randomized placebocontrolled study (21), adult height measurements were available for 33 of 68 subjects who received either GH with a dose of 0.22 mg/kg per week in 3 weekly doses for 4.4 years (mean) or placebo. The efficacy analysis demonstrated that the GH group achieved a significantly greater adult height than the placebo group (K1.81 vs K2.32 SDS respectively) by 0.51 SDS (3.7 cm; PZ0.02; 95% confidence interval (CI)Z 0.10–0.92 SDS). Many subjects lacked adult height measurements, but two modified intent-to-treat analyses showed that height SDS gave a GH treatment effect similar to the primary efficacy analysis (0.52 SDS; 3.8 cm). DOI: 10.1530/eje.1.02244 Online version via www.eje-online.org

S36

L Dunkel

EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006) 155

At adult height measurement, or at last observation for analyses that included patients without adult height measurements, there were no statistically significant differences between treatment groups in treatment duration, chronological age or bone age. Mean height velocity was significantly greater in the GH group compared with the placebo group during the first 2 years of therapy, and consequently, height SDS increased in GH-treated patients compared with controls, whereas bone age progression was similar. In the dose–response study (22), subjects were treated with GH at 0.24 mg/kg per week, 0.24 mg/kg per week for the first year and 0.37 mg/kg per week thereafter (0.24/0.37), or 0.37 mg/kg per week. Final height measurements were available for 50 patients at study completion (mean treatment duration, 6.5 years). For these 50 subjects, mean height SDS increased by 1.55, 1.52 and 1.85 for the dose groups of 0.24, 0.24/0.37 and 0.37 mg/kg per week respectively. For the primary comparison between 0.37 mg/kg per week and 0.24 mg/kg per week dose groups, the mean treatment difference (adjusted for differences in baseline-predicted height SDS) was 0.57 SDS (3.6 cm; PZ0.025). Mean overall height gains (final height minus baseline-predicted height) were 7.2 and 5.4 cm for 0.37 and 0.24 mg/kg per week dose groups respectively. Derived from the placebo-controlled and the dose– response study, Fig. 1 provides an approach to estimate the overall efficacy of a 0.37 mg/kg per week dose in ISS. The incremental effect of 0.37 compared to 0.24 mg/kg per week, estimated from the dose–response study was 3.6 cm (22). The overall effect of the 0.24 mg/kg per week dosage can be estimated roughly to be 3.7 cm from the results of the slightly lower dosage of the placebocontrolled study (21). These data together suggest that the overall treatment effect of 0.37 mg/kg per week is approximately, 3.6G3.7Z7.3 cm.

Final height SDS

0.0

Placebo-controlled (ref. 21) GH (mg/kg/wk) Placebo 0.22 n = 10 n = 22

Safety of GH treatment in ISS Most of the published data on the safety of GH treatment in ISS derive from large post-marketing research programmes. These observational studies have reported safety data for approximately 9000 patients with ISS, representing approximately 27 000 patient-years of GH exposure. Overall, adverse event (AE) rates for these patients with ISS have been similar to, or in some cases, lower than AE rates for patients with other GH-treated conditions (23, 24). For example, patients with ISS comprised 17.1% of the total National Cooperative Growth Study population, but accounted for only 4.6% of all serious AEs and 3.4% of deaths, the fewest of any of the patient populations (23). Similarly, patients with ISS had the lowest overall AE rate of all patient groups examined in the Kabi International Growth Study (5). One report provides safety data from the two randomized registration studies in patients with ISS that formed the basis of the FDA approval for GH treatment of this form of short stature (25). In this report, a perspective of GH safety is provided in ISS relative to other patient groups for whom GH treatment is well established. The ISS AE data were compared with the AE data derived from registration studies of GH deficiency (GHD) and Turner syndrome (TS). In the ISS studies (21, 22), serious AEs (mainly hospitalizations for accidental injury or acute illness unrelated to GH exposure) were reported for 13–14% of GH-treated patients. Overall, AE rates (serious and non-serious) as well as rates of potentially GH-related

Dose-response (ref. 22) GH (mg/kg/wk) 0.0

–0.5

–0.5

–1.0

–1.0

–1.5

–1.5

–2.0

3.7 –2.0 cm

–2.5

–2.5

www.eje-online.org

The Food and Drug Administration (FDA) approved the use of biosynthetic GH for the treatment of children with idiopathic short stature (ISS) in the US in 2003, based primarily on these two studies (21, 22) demonstrating an increase in adult height over the predicted height at baseline and over placebo-treated controls by an average of 4–7 cm.

0.24

0.37

n = 17

n = 17

3.6 cm

7.3 cm

Figure 1 The overall treatment effect of a 0.37 mg/kg per week GH dose, estimated from the placebo-controlled study (21) and dose–response study (22). In the dose–response study, the incremental effect of 0.37 compared with 0.24 mg/kg per week was 3.6 cm. The overall effect of the 0.24 dosage, estimated from the results of the slightly lower dosage of the placebocontrolled study was 3.7 cm. Taken together, these data suggest that the overall treatment effect of 0.37 mg/kg per week was approximately 7.3 cm. The placebo-controlled study results are from an analysis of covariance with baselinepredicted height SDS as the covariate. The dose– response study results are from a general linear model with an adjusted value for baselinepredicted height SDS for those patients who have baseline-predicted height SDS and an unadjusted value for those patients missing baseline-predicted height SDS.

Children with idiopathic short stature


AEs were similar in the GHD, TS and ISS studies (for ISS studies combined: otitis media 8%; scoliosis 3%; hypothyroidism, 0.7%; changes in carbohydrate metabolism 0.7% and hypertension 0.4%). Measures of carbohydrate metabolism were not affected by GH treatment in patients with ISS. There was no significant GH effect on fasting blood glucose in either study (GH dose range, 0.22–0.37 mg/kg per week) or insulin sensitivity (placebo-controlled study only). Overall, the data on the dearth of severe adverse events found in all safety studies are important and reassuring. However, there are some limitations in the approaches used in these studies (24). The approach of assessing GH safety in ISS by comparing this population (which, by definition, does not have co-morbid conditions) with children, who have disorders with intrinsic heightened health risks (Turner syndrome; classical GH deficiency) is potentially problematic. The drug exposure was approximately 4 years on average in one study (21) and, in the other, a maximum of 7 years exposure was reported in cohorts assessed for efficacy (the average drug exposure in the full cohort was not specified) (22). Some patients included in the safety analyses had only one GH injection and others ceased study participation before receiving any GH. Limited drug exposure potentially underestimates risk assessment. Furthermore, in a situation of relatively short drug exposure for many subjects, expression of data in terms of patient-years of exposure can be confusing and misinterpreted. In both studies (21, 22), there was considerable subject attrition, potentially further limiting the ability to assess the frequency of adverse events. Both studies included many patients, who received GH in lower doses than those approved by the FDA, now raising questions about data applicability to future safety. Thus, it is unclear whether either study has the statistical power to detect increased risks. The power to detect small increases in risk with drug use depends on the size of the cohort, “with large cohorts needed to reliably demonstrate increased risks of even two- to three-fold” (25). With these reservations, GH appears safe in ISS, but the studies have not been powered to assess the frequency of rare GH-related events and long-term follow-up studies of GH-treated patients with ISS are warranted.

Conclusions Safety of any treatment is not an absolute concept, but should be considered in relation to the morbidity of the untreated state, the benefit to be gained from treatment and alternative management approaches (25). We often accept unknown risks for the treatment of serious and/ or life threatening diseases. However, ISS may not be considered a life-threatening condition. Furthermore, evidence of morbidity caused by ISS is scant. Therefore, interpretation of available safety data for GH must be

S37

done in relation to treatment effectiveness in meeting the therapeutic goals. If the goal is any gain in height for children with ISS, GH can generally be considered effective. Although there are exceptions; data suggest that several years of GH treatment for children with ISS can increase their adult height by, on average, 4–7 cm. If, however, the goal is improvement in psychosocial status or well-being through height gain, the data are less clear. Recent data suggest that few children with ISS have significant psychosocial morbidity (26). Without demonstration of an evident baseline morbidity, as is the case for ISS to date (27), it is difficult to demonstrate that a treatment improves well-being. The key issue is whether the available data on GH safety in ISS combined with available data on its efficacy, are sufficient to warrant widespread GH use today? There is currently no clear answer to this question.

References 1 Wit JM, Boersma B, de Muinck Keizer-Schrama SM, Nienhuis HE, Oostdijk W, Otten BJ, Delemarre-Van de Waal HA, Reeser M, Waelkens JJ, Rikken B & Massa GG. Long-term results of growth hormone therapy in children with short stature, subnormal growth rate and normal growth hormone response to secretagogues. Clinical Endocrinology 1995 42 365–372. 2 Root AW, Kemp SF, Rundle AC, Dana K & Attie KM. Effect of longterm recombinant growth hormone therapy in children – the National Cooperative Growth Study, USA, 1985–1994. Journal of Pediatric Endocrinology and Metabolism 1998 11 403–412. 3 Cuttler L, Silvers JB, Singh J, Marrero U, Finkelstein B, Tannin G & Neuhauser D. Short stature and growth hormone therapy. A national study of physician recommendation patterns. JAMA 1996 276 531–537. 4 Maneatis T, Baptista J, Connelly K & Blethen S. Growth hormone safety update from the National Cooperative Growth Study. Journal of Pediatric Endocrinology and Metabolism 2000 13 1035–1044. 5 Wilton P. Adverse events during GH treatment: 10 years’ experience in KIGS, a pharmacoepidemiological survey. In Growth Hormone Therapy in KIGS – 10 years’ Experience, pp 349–364. Eds MB Ranke & P Wilton, Heidelberg: Johann Ambrosius Barth Verlag, 1999. 6 Hopwood NJ, Hintz RL, Gertner JM, Attie KM, Johanson AJ, Baptista J, Kuntze J, Blizzard RM, Cara JF, Chernausek SD, Kaplan SL, Lippe BM, Plotnick LP & Saenger P. Growth response of children with nongrowth hormone deficiency and marked short stature during three years of growth hormone therapy. Journal of Pediatrics 1993 123 215–222. 7 Barton JS, Gargineri HM, Cullen S, Hindmarsh PC, Brook CG & Preece MA. The growth and cardiovascular effects of high dose growth hormone therapy in idiopathic short stature. Clinical Endocrinology 1995 42 619–626. 8 Lanes R. Effects of two years of growth hormone treatment in short, slowly growing non-growth hormone deficient children. Journal of Pediatric Endocrinology and Metabolism 1995 8 167–171. 9 Hintz RL, Attie KM, Baptista J & Roche A. Effect of growth hormone treatment on adult height of children with idiopathic short stature. New England Journal of Medicine 1999 340 502–507. 10 Kawai M, Momoi T, Yorifuji T, Yhamanaka C, Sasaki H & Furusho K. Unfavorable effects of growth hormone therapy on the final height of boys with short stature not caused by growth hormone deficiency. Journal of Pediatrics 1997 130 205–209. 11 Bernasconi S, Street ME, Volta C & Mazzardo G. Final height in nongrowth hormone deficient children treated with growth hormone. Clinical Endocrinology 1997 47 261–266.

www.eje-online.org

S38

L Dunkel

12 Wit JM, Kamp GA & Rikken B. Spontaneous growth and response to growth hormone treatment in children with growth hormone deficiency and idiopathic short stature. Pediatric Research 1996 39 295–302. 13 Loche S, Cambiaso P, Setzu S, Carta D, Marini R, Borrelli P & Cappa M. Final height after growth hormone therapy in non-growthhormone-deficient short stature. Journal of Pediatrics 1994 125 196–200. 14 Zadik A & Amnon Z. Final height after growth hormone therapy in short children: correlation with siblings’ height. Hormone Research 1997 48 274–277. 15 Buchlis JG, Irizarry L, Crotzer BC, Shine BJ, Allen L & MacGillivray MH. Comparison of final heights of growth hormone-treated vs. untreated children with idiopathic growth failure. Journal of Clinical Endocrinology and Metabolism 1998 83 1075–1079. 16 Lo´pez-Siguero JP, Garcı´a-Garcia E, Carralero I & Martı´nez-Aedo MJ. Adult height in children with idiopathic short stature treated with growth hormone. Journal of Pediatric Endocrinology and Metabolism 2000 13 1595–1602. 17 Coutant R, Rouleau S, Despert F, Magontier N, Loisel D & Limal J-M. Growth and adult height in GH-treated children with nonacquired GH deficiency and idiopathic short stature: the influence of pituitary magnetic resonance imaging findings. Journal of Clinical Endocrinology and Metabolism 2001 86 4649–4654. 18 Hindmarsh PC & Brook CGD. Final height of short normal children treated with growth hormone. Lancet 1996 348 13–16. 19 Finkelstein BS, Imperiale TF, Speroff T, Marrero U, Radcliffe D & Cuttler L. Effect of Growth hormone therapy on height in children with idiopathic short stature. Archives of Pediatrics and Adolescent Medicine 2002 156 230–240. 20 McCaughey ES, Mulligan J, Voss LD & Betts PR. Randomised trial of growth hormone in short normal girls. Lancet 1998 351 940–944. 21 Leschek EW, Rose SR, Yanovski JA, Troendle JF, Quigley CA, Chipman JJ, Crowe BJ, Ross JL, Cassorla FG, Blum WF, Cutler GB Jr

www.eje-online.org


22

23

24

25

26

27

& Baron J. Effect of growth hormone treatment on adult height in peripubertal children with idiopathic short stature: a randomized, double-blind, placebo-contro trial. Journal of Clinical Endocrinology and Metabolism 2004 89 3140–3148. Wit JM, Rekers-Mombarg LTM, Cutler DG Jr, Crowe B, Beck TB, Roberts K, Gill A, Chaussain JL, Frisch H, Yturriaga R & Attanasio AF. Growth hormone (GH) treatment to final height in children with idiopathic short stature: evidence for a dose effect. Journal of Pediatrics 2005 146 45–53. Maneatis T, Baptista J, Connelly K & Blethen S. Growth hormone safety update from the National Cooperative Growth Study. Journal of Pediatric Endocrinology and Metabolism 2000 13 1035–1044. Quigley CA, Gill AM, Crowe BJ, Robling K, Chipman JJ, Rose SR, Ross JL, Cassorla FG, Wolka AM, Wit JM, Rekers-Mombarg LTM & Cutler DG Jr. Safety of growth hormone treatment in pediatric patients with idiopathic short stature. Journal of Clinical Endocrinology and Metabolism 2005 90 5188–5196. Brewer T & Colditz GA. Postmarketing surveillance and adverse drug reactions – current perspectives and future needs. JAMA 1999 281 824–829. Sandberg DE, Bukowski WM, Fung CM & Noll RB. Height and social adjustment: are extremes a cause for concern and action? Pediatrics 2004 114 744–750. Downie AB, Mulligan J, McCaughey ES, Stratford RJ, Betts PR & Voss LD. Psychological response to growth hormone treatment in short normal children. Archives of Disease in Childhood 1996 75 32–35.

Received 20 April 2006 Accepted 4 July 2006